Norris Medicines Board Meeting on Nov 14 for Un-Audited Results

Norris Medicines Ltd has announced that its Board of Directors will convene on November 14, 2026, to consider and approve the Un-audited Financial Results for the quarter and half-year ended September 30, 2026. The meeting will also include a review of the Limited Review Report. Concurrently, the company has maintained its trading window closure for securities from October 1, 2026, until 48 hours post the declaration of these financial results, in line with SEBI's insider trading regulations.